Regulus Therapeutics Inc’s stock market performance has been consistent. The 1-year high for the company’s stock was recorded at $3.79 on 03/12/24, with the lowest value being $1.08 on 01/17/24.
52-week price history of RGLS Stock
Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. Regulus Therapeutics Inc’s current trading price is -55.94% away from its 52-week high, while its distance from the 52-week low is 54.63%. The stock’s price range for this period has remained between $1.08 and $3.79. The Healthcare sector company’s shares managed to surpass a trading volume of around 1.05 million for the day, which was noticeably higher compared to the shares’ average daily volume of 0.38 million over the last three months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Financial Performance and Market Capitalization
Regulus Therapeutics Inc (RGLS) has experienced a quarterly decline of -7.22% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 109.33M and boasts a workforce of 30 employees.
Moving average and trading volume data
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.8331, with a change in price of -0.5800. Similarly, Regulus Therapeutics Inc recorded 660,234 in trading volume during the last 100 days, posting a change of -25.78%.
RGLS Debt-to-equity ratio analysis
The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for RGLS stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.01.
RGLS Stock Stochastic Average
As of today, the raw stochastic average of Regulus Therapeutics Inc over the last 50 days is at 51.79%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 61.97%. Further, the company’s Stochastic %K and %D values for the last 20 days were 48.43% and 45.35%, respectively.
RGLS Stock Price Performance Analysis
The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. Until today this year the stock’s price performance recorded an increase of 30.47%. However, over the last six months, the performance has been stronger by -36.02%. The price of RGLS increased 6.37% over the last 30 days. And in the last five days, it has surged by 5.03%.
